Aura Biosciences (NASDAQ:AURA – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
A number of other equities analysts have also commented on AURA. Citigroup restated a “market outperform” rating on shares of Aura Biosciences in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aura Biosciences in a research note on Monday, October 12th. Finally, HC Wainwright dropped their price objective on shares of Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.50.
Read Our Latest Research Report on AURA
Aura Biosciences Price Performance
Aura Biosciences (NASDAQ:AURA – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.08. As a group, equities analysts forecast that Aura Biosciences will post -1.48 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC grew its holdings in Aura Biosciences by 29.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,807,300 shares of the company’s stock worth $23,910,000 after acquiring an additional 856,270 shares during the last quarter. 49 Wealth Management LLC bought a new position in shares of Aura Biosciences in the third quarter worth about $111,000. HighTower Advisors LLC bought a new position in shares of Aura Biosciences in the third quarter worth about $110,000. Russell Investments Group Ltd. raised its stake in shares of Aura Biosciences by 203.6% in the third quarter. Russell Investments Group Ltd. now owns 54,618 shares of the company’s stock worth $343,000 after acquiring an additional 36,628 shares during the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Aura Biosciences by 74.0% during the third quarter. Parallel Advisors LLC now owns 9,857 shares of the company’s stock worth $62,000 after purchasing an additional 4,192 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.
Aura Biosciences Company Profile
Aura Biosciences is a clinical-stage biotechnology company developing treatments for cancer, with a focus on therapies designed to selectively destroy tumor cells while limiting damage to surrounding healthy tissue. The company is headquartered in the Boston area. Its lead candidate, belzupacap sarotalocan (formerly AU-011), is an investigational therapy being studied for choroidal melanoma, a cancer that develops in the eye. It uses a virus-like particle linked to a light-activated compound; after the compound binds to tumor cells, near-infrared light activates it to damage those cells.
Read More
- Five stocks we like better than Aura Biosciences
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
